Taken together, these data suggest that the cisplatin-activated JNK-cJUN axis contributes to the upregulation of XRCC4 in the cisplatin-resistant ovarian cancer cells exposed to cisplatin. Here, XRCC4 is linked to ovarian carcinoma.